ERBB2 and cancer: Analysis revealed that high expression of JAM-A mRNA in HER2-positive GE cancers carried a significantly greater risk of both poorer overall patient survival (p = 0.033; Figure 1A) and poorer survival in patients whose cancers progressed (p = 0.036; Figure 1C), although this was independent of the time to progression (Figure 1B).